![Anne Johnson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Anne Johnson
Director of Finance/CFO at ATAI LIFE SCIENCES N.V.
Net worth: 115 536 $ as of 2024-05-30
Anne Johnson active positions
Companies | Position | Start | End |
---|---|---|---|
ATAI LIFE SCIENCES N.V. | Comptroller/Controller/Auditor | 2020-12-31 | - |
Director of Finance/CFO | 2023-10-12 | - |
Career history of Anne Johnson
Former positions of Anne Johnson
Companies | Position | Start | End |
---|---|---|---|
CHIMERIX, INC. | Comptroller/Controller/Auditor | - | - |
Xanodyne Pharmaceuticals, Inc.
![]() Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Director of Finance/CFO | - | - |
Aruvant Sciences, Inc.
![]() Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Comptroller/Controller/Auditor | - | - |
Training of Anne Johnson
The University of North Carolina at Wilmington | Undergraduate Degree |
Statistics
International
United States | 5 |
Germany | 2 |
Operational
Comptroller/Controller/Auditor | 3 |
Director of Finance/CFO | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
CHIMERIX, INC. | Health Technology |
ATAI LIFE SCIENCES N.V. | Health Technology |
Private companies | 2 |
---|---|
Xanodyne Pharmaceuticals, Inc.
![]() Xanodyne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY. | Health Technology |
Aruvant Sciences, Inc.
![]() Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Anne Johnson
- Experience